Correlation Between Nurix Therapeutics and Intellia Therapeutics
Can any of the company-specific risk be diversified away by investing in both Nurix Therapeutics and Intellia Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nurix Therapeutics and Intellia Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nurix Therapeutics and Intellia Therapeutics, you can compare the effects of market volatilities on Nurix Therapeutics and Intellia Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nurix Therapeutics with a short position of Intellia Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nurix Therapeutics and Intellia Therapeutics.
Diversification Opportunities for Nurix Therapeutics and Intellia Therapeutics
0.2 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Nurix and Intellia is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding Nurix Therapeutics and Intellia Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Intellia Therapeutics and Nurix Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nurix Therapeutics are associated (or correlated) with Intellia Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Intellia Therapeutics has no effect on the direction of Nurix Therapeutics i.e., Nurix Therapeutics and Intellia Therapeutics go up and down completely randomly.
Pair Corralation between Nurix Therapeutics and Intellia Therapeutics
Given the investment horizon of 90 days Nurix Therapeutics is expected to generate 0.79 times more return on investment than Intellia Therapeutics. However, Nurix Therapeutics is 1.27 times less risky than Intellia Therapeutics. It trades about -0.05 of its potential returns per unit of risk. Intellia Therapeutics is currently generating about -0.1 per unit of risk. If you would invest 2,444 in Nurix Therapeutics on September 5, 2024 and sell it today you would lose (355.00) from holding Nurix Therapeutics or give up 14.53% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 98.44% |
Values | Daily Returns |
Nurix Therapeutics vs. Intellia Therapeutics
Performance |
Timeline |
Nurix Therapeutics |
Intellia Therapeutics |
Nurix Therapeutics and Intellia Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Nurix Therapeutics and Intellia Therapeutics
The main advantage of trading using opposite Nurix Therapeutics and Intellia Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nurix Therapeutics position performs unexpectedly, Intellia Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Intellia Therapeutics will offset losses from the drop in Intellia Therapeutics' long position.Nurix Therapeutics vs. Foghorn Therapeutics | Nurix Therapeutics vs. Shattuck Labs | Nurix Therapeutics vs. Monte Rosa Therapeutics | Nurix Therapeutics vs. Kymera Therapeutics |
Intellia Therapeutics vs. Editas Medicine | Intellia Therapeutics vs. Caribou Biosciences | Intellia Therapeutics vs. Crispr Therapeutics AG | Intellia Therapeutics vs. Verve Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Global Correlations Find global opportunities by holding instruments from different markets |